Lansoprazole oro-dispersible tablet (Zoton FasTab®) for the eradication of Helicobacter pylori

The Scottish Medicines Consortium issues advice on lansoprazole oro-dispersible tablet (Zoton FasTab), for use within NHS Scotland.

The Scottish Medicines Consortium (SMC) has completed its assessment on the above product. The SMC advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) that lansoprazole oro-dispersible tablet (Zoton FasTab) is accepted for use in NHS Scotland, in combination with appropriate antibiotics, for the eradication of Helicobacter pylori from the upper gastrointestinal tract in patients with ulcer-like dyspepsia in whom Helicobacter pylori infection has been demonstrated. The standard formulation of lansoprazole also has this indication.